NRX Pharmaceuticals, Inc. Common Stock (NRXP) Stock
NASDAQ · NRXP
3.37
Fundamentals
Market cap
$146.77M
Price / Earnings ratio
-6.2x
Price / Sales ratio
42.7x
Price / Book ratio
-852.9x
Return on assets
-2.2%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About NRX Pharmaceuticals, Inc. Common Stock
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
SectorHealthcare
IndustryBiotechnology
Employees29
CEODr. Jonathan C. Javitt M.D., M.P.H.
IPO DateDec 4, 2017
HeadquartersWilmington, DE
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chairman & CEO | 1957 |
| Mr. Michael S. Abrams M.B.A. | CFO & Treasurer | 1970 |
| Mr. Joseph M. Casper | Chief Operating Officer | 1951 |
| Dr. Riccardo Panicucci Ph.D. | Chief Manufacturing & Technology Officer | 1962 |
| Dr. Hervé Perron HDR, Ph.D. | Chief Scientist | 1959 |
| Suzanne Messere | Investor Relations | — |
Fundamentals
Valuation
Market cap$146.77M
Price-to-sales ratio42.72
Price-to-book value-852.94
Price-earnings ratio-6.20
Return on Equity108.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.55
Income Statement
Average volume709,167
EBITDA$-23.33M
1 year high (52w)$5.06
1 year low (52w)$1.62
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



